However, if such loss may have, on one side, a positive effect on specific features of the disorder, (e.g. bone marrow progenitors), on the other side it may increase patients’ cancer risk, by the selection of p53 compromised cells (see Figure 6). This evidence concerns the gene TP53 and cancer.